Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
Identifieur interne : 008D74 ( Main/Exploration ); précédent : 008D73; suivant : 008D75Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
Auteurs : Paul D. Miller [États-Unis] ; Pierre D. Delmas [France] ; Robert Lindsay [États-Unis] ; Nelson B. Watts [États-Unis] ; Marjorie Luckey [États-Unis] ; Jonathan Adachi [Canada] ; Kenneth Saag [États-Unis] ; Susan L. Greenspan [États-Unis] ; Ego Seeman [Australie] ; Steven Boonen [Belgique] ; Suzanne Meeves [États-Unis] ; Thomas F. Lang [États-Unis] ; John P. Bilezikian [États-Unis]Source :
- The Journal of clinical endocrinology and metabolism [ 0021-972X ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Background: Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate. Methods: Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups. We also examined changes in other bone turnover markers, bone mineral density (BMD), and relationships between early changes in bone turnover markers and 12-month areal and volumetric BMD. Results: In the prior risedronate group, the N-terminal propeptide of type 1 collagen increase was significantly greater after 3 months of teriparatide than in the prior alendronate group (mean ± SE, 86.0 ± 5.6 vs. 61.2 ± 5.3 ng/ml, respectively; P < 0.001). Findings were similar for the other bone turnover markers. The changes in areal BMD and trabecular spine volumetric BMD were also greater in the prior risedronate group (P < 0.05). Early changes in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12 months (Spearman r = 0.45). Teriparatide was well tolerated. Conclusion: This nonrandomized but prospective study suggests that there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure.
Url:
Affiliations:
- Australie, Belgique, Canada, France, États-Unis
- Auvergne-Rhône-Alpes, Province du Brabant flamand, Rhône-Alpes, Victoria (État)
- Louvain, Lyon, Melbourne
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 003242
- to stream PascalFrancis, to step Curation: 002E11
- to stream PascalFrancis, to step Checkpoint: 003285
- to stream Main, to step Merge: 009699
- to stream Pmc, to step Corpus: 001920
- to stream Pmc, to step Curation: 001779
- to stream Pmc, to step Checkpoint: 002A15
- to stream Ncbi, to step Merge: 000429
- to stream Ncbi, to step Curation: 000429
- to stream Ncbi, to step Checkpoint: 000429
- to stream Main, to step Merge: 008E56
- to stream Main, to step Curation: 008D74
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate</title><author><name sortKey="Miller, Paul D" sort="Miller, Paul D" uniqKey="Miller P" first="Paul D." last="Miller">Paul D. Miller</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Colorado Center for Bone Research</s1><s2>Lakewood, Colorado 80227</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Colorado Center for Bone Research</wicri:noRegion></affiliation></author><author><name sortKey="Delmas, Pierre D" sort="Delmas, Pierre D" uniqKey="Delmas P" first="Pierre D." last="Delmas">Pierre D. Delmas</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut National de la Santé et de la Recherche Médicale Research Unit 831 and Claude Bernard University Lyon 1</s1><s2>69372 Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>69372 Lyon</wicri:noRegion><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author><author><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Regional Bone Center Helen Hayes Hospital</s1><s2>West Haverstraw, New York 10993</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Regional Bone Center Helen Hayes Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Cincinnati Bone Health and Osteoporosis Center</s1><s2>Cincinnati, Ohio 45219</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Cincinnati Bone Health and Osteoporosis Center</wicri:noRegion></affiliation></author><author><name sortKey="Luckey, Marjorie" sort="Luckey, Marjorie" uniqKey="Luckey M" first="Marjorie" last="Luckey">Marjorie Luckey</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>St. Barnabas Osteoporosis Center</s1><s2>Livingston, New Jersey 07039</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>St. Barnabas Osteoporosis Center</wicri:noRegion></affiliation></author><author><name sortKey="Adachi, Jonathan" sort="Adachi, Jonathan" uniqKey="Adachi J" first="Jonathan" last="Adachi">Jonathan Adachi</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>St. Joseph's Healthcare McMaster University</s1><s2>Hamilton, Ontario, L8S4L8</s2><s3>CAN</s3><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>St. Joseph's Healthcare McMaster University</wicri:noRegion></affiliation></author><author><name sortKey="Saag, Kenneth" sort="Saag, Kenneth" uniqKey="Saag K" first="Kenneth" last="Saag">Kenneth Saag</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham</s1><s2>Birmingham, Alabama 35233</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham</wicri:noRegion></affiliation></author><author><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University of Pittsburgh Medical Center</s1><s2>Pittsburgh, Pennsylvania 15213</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Pittsburgh Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Seeman, Ego" sort="Seeman, Ego" uniqKey="Seeman E" first="Ego" last="Seeman">Ego Seeman</name><affiliation wicri:level="4"><inist:fA14 i1="09"><s1>Endocrinology Department Austin Health, University of Melbourne</s1><s2>Victoria 3010</s2><s3>AUS</s3><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Bone Research Unit Leuven University, Department of Experimental Medicine</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Meeves, Suzanne" sort="Meeves, Suzanne" uniqKey="Meeves S" first="Suzanne" last="Meeves">Suzanne Meeves</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sanofi-aventis</s1><s2>Bridgewater, New Jersey 08807</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Sanofi-aventis</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Thomas F" sort="Lang, Thomas F" uniqKey="Lang T" first="Thomas F." last="Lang">Thomas F. Lang</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Radiology Center for Molecular and Functional Imaging, University of California at San Francisco</s1><s2>San Francisco, California 94107</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>San Francisco, California 94107</wicri:noRegion></affiliation></author><author><name sortKey="Bilezikian, John P" sort="Bilezikian, John P" uniqKey="Bilezikian J" first="John P." last="Bilezikian">John P. Bilezikian</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Division of Endocrinology Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons</s1><s2>New York, New York 10021</s2><s3>USA</s3><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New York, New York 10021</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0499193</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0499193 INIST</idno><idno type="RBID">Pascal:08-0499193</idno><idno type="wicri:Area/PascalFrancis/Corpus">003242</idno><idno type="wicri:Area/PascalFrancis/Curation">002E11</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003285</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003285</idno><idno type="wicri:doubleKey">0021-972X:2008:Miller P:early:responsiveness:of</idno><idno type="wicri:Area/Main/Merge">009699</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399468</idno><idno type="RBID">PMC:5399468</idno><idno type="wicri:Area/Pmc/Corpus">001920</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001920</idno><idno type="wicri:Area/Pmc/Curation">001779</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001779</idno><idno type="wicri:Area/Pmc/Checkpoint">002A15</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002A15</idno><idno type="wicri:Area/Ncbi/Merge">000429</idno><idno type="wicri:Area/Ncbi/Curation">000429</idno><idno type="wicri:Area/Ncbi/Checkpoint">000429</idno><idno type="wicri:doubleKey">0021-972X:2008:Miller P:early:responsiveness:of</idno><idno type="wicri:Area/Main/Merge">008E56</idno><idno type="wicri:Area/Main/Curation">008D74</idno><idno type="wicri:Area/Main/Exploration">008D74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate</title><author><name sortKey="Miller, Paul D" sort="Miller, Paul D" uniqKey="Miller P" first="Paul D." last="Miller">Paul D. Miller</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Colorado Center for Bone Research</s1><s2>Lakewood, Colorado 80227</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Colorado Center for Bone Research</wicri:noRegion></affiliation></author><author><name sortKey="Delmas, Pierre D" sort="Delmas, Pierre D" uniqKey="Delmas P" first="Pierre D." last="Delmas">Pierre D. Delmas</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut National de la Santé et de la Recherche Médicale Research Unit 831 and Claude Bernard University Lyon 1</s1><s2>69372 Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>69372 Lyon</wicri:noRegion><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author><author><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Regional Bone Center Helen Hayes Hospital</s1><s2>West Haverstraw, New York 10993</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Regional Bone Center Helen Hayes Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Cincinnati Bone Health and Osteoporosis Center</s1><s2>Cincinnati, Ohio 45219</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Cincinnati Bone Health and Osteoporosis Center</wicri:noRegion></affiliation></author><author><name sortKey="Luckey, Marjorie" sort="Luckey, Marjorie" uniqKey="Luckey M" first="Marjorie" last="Luckey">Marjorie Luckey</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>St. Barnabas Osteoporosis Center</s1><s2>Livingston, New Jersey 07039</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>St. Barnabas Osteoporosis Center</wicri:noRegion></affiliation></author><author><name sortKey="Adachi, Jonathan" sort="Adachi, Jonathan" uniqKey="Adachi J" first="Jonathan" last="Adachi">Jonathan Adachi</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>St. Joseph's Healthcare McMaster University</s1><s2>Hamilton, Ontario, L8S4L8</s2><s3>CAN</s3><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>St. Joseph's Healthcare McMaster University</wicri:noRegion></affiliation></author><author><name sortKey="Saag, Kenneth" sort="Saag, Kenneth" uniqKey="Saag K" first="Kenneth" last="Saag">Kenneth Saag</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham</s1><s2>Birmingham, Alabama 35233</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham</wicri:noRegion></affiliation></author><author><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University of Pittsburgh Medical Center</s1><s2>Pittsburgh, Pennsylvania 15213</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Pittsburgh Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Seeman, Ego" sort="Seeman, Ego" uniqKey="Seeman E" first="Ego" last="Seeman">Ego Seeman</name><affiliation wicri:level="4"><inist:fA14 i1="09"><s1>Endocrinology Department Austin Health, University of Melbourne</s1><s2>Victoria 3010</s2><s3>AUS</s3><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Bone Research Unit Leuven University, Department of Experimental Medicine</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Meeves, Suzanne" sort="Meeves, Suzanne" uniqKey="Meeves S" first="Suzanne" last="Meeves">Suzanne Meeves</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sanofi-aventis</s1><s2>Bridgewater, New Jersey 08807</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Sanofi-aventis</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Thomas F" sort="Lang, Thomas F" uniqKey="Lang T" first="Thomas F." last="Lang">Thomas F. Lang</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Radiology Center for Molecular and Functional Imaging, University of California at San Francisco</s1><s2>San Francisco, California 94107</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>San Francisco, California 94107</wicri:noRegion></affiliation></author><author><name sortKey="Bilezikian, John P" sort="Bilezikian, John P" uniqKey="Bilezikian J" first="John P." last="Bilezikian">John P. Bilezikian</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Division of Endocrinology Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons</s1><s2>New York, New York 10021</s2><s3>USA</s3><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New York, New York 10021</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">The Journal of clinical endocrinology and metabolism</title><title level="j" type="abbreviated">J. clin. endocrinol. metab.</title><idno type="ISSN">0021-972X</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Journal of clinical endocrinology and metabolism</title><title level="j" type="abbreviated">J. clin. endocrinol. metab.</title><idno type="ISSN">0021-972X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Alendronic acid</term><term>Antiosteoporotic</term><term>Antiresorptive agent</term><term>Early</term><term>Endocrinology</term><term>Female</term><term>Human</term><term>Metabolic diseases</term><term>Nutrition</term><term>Nutritional status</term><term>Obesity</term><term>Osteoporosis</term><term>Risedronic acid</term><term>Teriparatide</term><term>Treatment</term><term>Woman</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Ostéoporose</term><term>Précoce</term><term>Homme</term><term>Tériparatide</term><term>Femelle</term><term>Femme</term><term>Acide alendronique</term><term>Adulte</term><term>Traitement</term><term>Acide risédronique</term><term>Endocrinologie</term><term>Maladie métabolique</term><term>Nutrition</term><term>Obésité</term><term>Antiostéoporotique</term><term>Antirésorptif</term><term>Etat nutritionnel</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Femme</term><term>Adulte</term><term>Nutrition</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate. Methods: Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups. We also examined changes in other bone turnover markers, bone mineral density (BMD), and relationships between early changes in bone turnover markers and 12-month areal and volumetric BMD. Results: In the prior risedronate group, the N-terminal propeptide of type 1 collagen increase was significantly greater after 3 months of teriparatide than in the prior alendronate group (mean ± SE, 86.0 ± 5.6 vs. 61.2 ± 5.3 ng/ml, respectively; P < 0.001). Findings were similar for the other bone turnover markers. The changes in areal BMD and trabecular spine volumetric BMD were also greater in the prior risedronate group (P < 0.05). Early changes in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12 months (Spearman r = 0.45). Teriparatide was well tolerated. Conclusion: This nonrandomized but prospective study suggests that there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Canada</li><li>France</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Province du Brabant flamand</li><li>Rhône-Alpes</li><li>Victoria (État)</li></region><settlement><li>Louvain</li><li>Lyon</li><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="États-Unis"><noRegion><name sortKey="Miller, Paul D" sort="Miller, Paul D" uniqKey="Miller P" first="Paul D." last="Miller">Paul D. Miller</name></noRegion><name sortKey="Bilezikian, John P" sort="Bilezikian, John P" uniqKey="Bilezikian J" first="John P." last="Bilezikian">John P. Bilezikian</name><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name><name sortKey="Lang, Thomas F" sort="Lang, Thomas F" uniqKey="Lang T" first="Thomas F." last="Lang">Thomas F. Lang</name><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name><name sortKey="Luckey, Marjorie" sort="Luckey, Marjorie" uniqKey="Luckey M" first="Marjorie" last="Luckey">Marjorie Luckey</name><name sortKey="Meeves, Suzanne" sort="Meeves, Suzanne" uniqKey="Meeves S" first="Suzanne" last="Meeves">Suzanne Meeves</name><name sortKey="Saag, Kenneth" sort="Saag, Kenneth" uniqKey="Saag K" first="Kenneth" last="Saag">Kenneth Saag</name><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Delmas, Pierre D" sort="Delmas, Pierre D" uniqKey="Delmas P" first="Pierre D." last="Delmas">Pierre D. Delmas</name></region></country><country name="Canada"><noRegion><name sortKey="Adachi, Jonathan" sort="Adachi, Jonathan" uniqKey="Adachi J" first="Jonathan" last="Adachi">Jonathan Adachi</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Seeman, Ego" sort="Seeman, Ego" uniqKey="Seeman E" first="Ego" last="Seeman">Ego Seeman</name></region></country><country name="Belgique"><region name="Province du Brabant flamand"><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008D74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008D74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:08-0499193
|texte= Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
}}
| This area was generated with Dilib version V0.6.33. |  |